Hypertension in Young Adults Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Elaine Ku, MD, MAS
- Phone Number: 415-476-7760
- Email: elaine.ku@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California San Francisco
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18-40 years of age
- Diagnosis of hypertension or receiving anti-hypertensive therapy OR Has clinical BP readings >130/80 mmHg that would meet the definition of hypertension and have home BP readings >=125/80 mmHg
Exclusion Criteria:
- are or are planning to become pregnant, due to inability to take multiple classes of anti- hypertensive agents
- are marginally housed, due to concerns regarding routine follow-up
- are actively participating in a different interventional trial that may affect blood pressure
- are unwilling to consent to participate
- institutionalized individuals or prisoners
- are actively abusing illicit drugs or alcohol
- have a history of poor or doubtful compliance (e.g., frequently missed appointments)
- have cognitive impairment prohibiting participation in the study
- History of allergy to any of the randomized medications
- Serum potassium >5.5 meq/L at the screening visit
- BP > 160/100 mmHg in clinic (stage II hypertension), regardless of whether patient is on therapy
- eGFR < 30 mL/min/1.73 m2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Amlodipine 2.5 mg + Home BP monitoring with cuffed device
Use of at least the minimum dose of amlodipine and use of a home BP monitoring device for BP monitoring
|
Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan.
All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
|
|
Experimental: Chlorthalidone 12.5 mg + Home BP monitoring with cuffed device
Use of at least the minimum dose of chlorthalidone and use of a home BP monitoring device for BP monitoring
|
Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan.
All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
|
|
Experimental: Losartan 12.5 mg daily + home BP monitoring with cuffed device
Use of at least the minimum dose of losartan and use of a home BP monitoring cuffed device only for BP monitoring
|
Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan.
All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
|
|
Experimental: amlodipine 2.5 mg daily + home BP monitoring with patch
Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a patch for BP monitoring
|
Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan.
All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
|
|
Experimental: Chlorthalidone 12.5 mg daily + home BP monitoring with patch
Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a patch for BP monitoring
|
Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan.
All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
|
|
Experimental: Losartan 12.5 mg daily + home BP monitoring with patch
Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a patch for BP monitoring
|
Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan.
All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
|
|
Experimental: amlodipine 2.5 mg daily + home BP monitoring with watch
Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a watch for BP monitoring
|
Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan.
All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
|
|
Experimental: chlorthalidone 12.5 mg daily + home BP monitoring with watch
Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a watch for BP monitoring
|
Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan.
All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
|
|
Experimental: losartan 12.5 mg daily + home BP monitoring with watch
Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a watch for BP monitoring
|
Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan.
All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Achieved systolic blood pressure
Time Frame: Month 6
|
Systolic blood pressure will be collected using at home cuffed devices.
The readings at end of the pilot trial (or most recent readings available) will be used for analysis of the primary outcome.
|
Month 6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence to home BP monitoring
Time Frame: Between month 0 and 6
|
Percent of weeks with at least 9 self-measured readings per week
|
Between month 0 and 6
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Elaine Ku, MD MAS, University of California, San Francisco
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Hypertension
- Calcium-Regulating Hormones and Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Membrane Transport Modulators
- Diuretics
- Natriuretic Agents
- Calcium Channel Blockers
- Vasodilator Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Sodium Chloride Symporter Inhibitors
- Antihypertensive Agents
- Amlodipine
- Chlorthalidone
- Losartan
Other Study ID Numbers
Other Study ID Numbers
- 21-35626
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.